Topic:

R&D

Latest Headlines

Latest Headlines

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.

PaxVax nails down $62M to complete vaccine buyout, PhIII study

Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200.

Antibiotics, lab safety and disease outbreaks top CDC Director Tom Frieden's to-do list

I caught up with Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, last week, prior to his address at the National Press Club in downtown Washington, DC. Other media outlets joined in later. Here are some takeaways from his speech on antibiotic resistance, as well as our conversation.

Apple poised to take a bite out of wearable device market with patent approved for iWatch

The patent for Apple's long anticipated iWatch has been approved, positioning the personal electronics giant to become one of the largest manufacturers of wearable medical devices in the world when the product is teamed with software applications that can track your heart rate and keep tabs on your blood sugar.

With billionaire's backing, Wyss spinout aims to retire animals in R&D

Over the past 5 years a team at Harvard's Wyss Institute for Biologically Inspired Engineering has been building a pioneering human "organ-on-a-chip" tech platform for discovery-based work on new therapies. And it's being spun out today to make a go of it as an independent company dubbed Emulate Inc., backed with a $12 million A round from a group that includes the billionaire founder of the institute that created the technology.

Google gathering data to build a picture of a healthy human

Google continued to reveal pieces of its expansion into life sciences this week, with a typically ambitious plan to map the characteristics of a healthy human the latest project to go public. The initiative is underpinned by Google's standard building blocks: data and computing horsepower.

Cancer researchers tap computers to support preclinical go/no-go decisions

Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.

Bayer's Nexavar misses another study endpoint, this time for breast cancer

Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication. 

Mayo Clinic, Enterprise Ireland partner to advance med tech

An interesting development in this age of Irish-fueled tax inversion deals, the  Mayo Clinic  and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.

Keryx touts its kidney drug with an FDA decision around the corner

Keryx Biopharmaceuticals' in-development Zerenex helped reduce dangerous buildups of phosphorus in patients on kidney dialysis, meeting its goals in a Phase III study as the company awaits final word from the FDA.